Effect of dual anti-platelet therapy on pocket hematoma after electrophysiological device placement
Abstract：Objective To investigate the incidence of pocket hematoma after electrophysiological device (EPD) placements in patients with dual anti-platelet (DAP) and low molecular weight heparin (LMWH) bridging.Methods One hundred and seventy-three patients with dual antiplatelet drug received the pacemaker implantation and enrolled in this prospective observational analysis.Eighty-seven patients received continue DAP therapy,86 patients replaced DAP drugs with enoxaparin bridging.The adenosine phosphate-mediated platelet aggregation and the ratio platelet aggregation induced by the arachidonic acid (AA) were tested before operation.The incidence of pocket hematoma was investigated.Results Incidence of pocket hematoma in continuing DAP group was lower than that of discontinue dual AP therapy with (LMWH) bridging therapy group (3.4％ vs 16.3 ％,x2 =11.73,P =0.003).Patients with LMWH bridging were 5.102 fold more likely to develop pocket hematoma than DAP individuals.A multiple Logistic regression analysis revealed that LMWH was an independent risk factor for the development of pocket hematoma (P =0.025).Conclusion Continuing dual anti-platelet therapy does not increase the risk of pocket hematoma after antiarrhythmic device placement.
Keywords：Dual anti-plateletPocket hematomaElectric pacemaker deviceLow molecular weight heparin bridging
Publication Date：2013-10-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：3( 1361-1363 )